Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro

A miR-124/ITGA3 axis contributes to colorectal cancer metastasis by regulating anoikis susceptibility

(2018) Ke-di Sa et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73

(2018) Qiruo Gao et al.   BIOMEDICINE & PHARMACOTHERAPY

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer

(2018) Marina Pulido et al.   BMC CANCER

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

(2018) David K. Lau et al.   BRITISH JOURNAL OF CANCER

Immune checkpoint inhibitors for metastatic bladder cancer

(2018) Francesco Massari et al.   CANCER TREATMENT REVIEWS

The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era

(2018) Sandy T. Liu et al.   Clinical Genitourinary Cancer

SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival

(2018) J. Y. Liu et al.   ONCOGENE

Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy

(2018) Anuja Sathe et al.   PLoS One

Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy

(2018) Brian R. Winters et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Acquired resistance to temsirolimus is associated with integrin α7 driven chemotactic activity of renal cell carcinoma in vitro

(2018) Tobias Engl et al.   Oncotarget

Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target

(2018) Jae Hun Jung et al.   CANCER LETTERS

Quantitative Proteomics Implicates Rictor/mTORC2 in Cell Adhesion

(2018) Hao Wang et al.   JOURNAL OF PROTEOME RESEARCH

HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression

(2018) Jasmina Makarević et al.   Cells

Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer

(2017) J. Alfred Witjes et al.   EUROPEAN UROLOGY

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

(2017) Philippe E. Spiess et al.   Journal of the National Comprehensive Cancer Network

The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling

(2017) Mee-Sup Yoon   Nutrients

Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases

(2017) Avileen Kaur et al.   INFLAMMOPHARMACOLOGY

FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence

(2016) Ana Blanca et al.   Biomarkers in Medicine

An integrin beta4-EGFR unit promotes hepatocellular carcinoma lung metastases by enhancing anchorage independence through activation of FAK–AKT pathway

(2016) Chao Leng et al.   CANCER LETTERS

mTOR inhibitors in urinary bladder cancer

(2016) R. Pinto-Leite et al.   TUMOR BIOLOGY

Kurzform der S3-Leitlinie Harnblasenkarzinom

(2016) M. Retz et al.   UROLOGE

Kurzform der S3-Leitlinie Harnblasenkarzinom

(2016) M. Retz et al.   UROLOGE

MicroRNA-31 functions as a tumor suppressor and increases sensitivity to mitomycin-C in urothelial bladder cancer by targeting integrin α5

(2016) Tianyuan Xu et al.   Oncotarget

The Role of Genomics in the Management of Advanced Bladder Cancer

(2015) Elizabeth A. Guancial et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Nicotine Induces Tumor Growth and Chemoresistance through Activation of the PI3K/Akt/mTOR Pathway in Bladder Cancer

(2015) K. Yuge et al.   MOLECULAR CANCER THERAPEUTICS

Cyclosporine A and tacrolimus inhibit urothelial tumorigenesis

(2015) Takashi Kawahara et al.   MOLECULAR CARCINOGENESIS

Surgical Advances in Bladder Cancer

(2015) David C. Johnson et al.   UROLOGIC CLINICS OF NORTH AMERICA

Expression of cyclin D1 and cyclin E in urothelial bladder carcinoma detected in tissue chips using a quantum dot immunofluorescence technique

(2015) GUANG SHAN et al.   Oncology Letters

GOLPH3 is a potential therapeutic target and a prognostic indicator of poor survival in bladder cancer treated by cystectomy

(2015) Qing Zhang et al.   Oncotarget

HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A

(2014) Eva Juengel et al.   Molecular Cancer

Comprehensive molecular characterization of urothelial bladder carcinoma

(2014)   NATURE

Amygdalin Blocks Bladder Cancer Cell Growth In Vitro by Diminishing Cyclin A and cdk2

(2014) Jasmina Makarević et al.   PLoS One

Resistance to the mTOR Inhibitor Temsirolimus Alters Adhesion and Migration Behavior of Renal Cell Carcinoma Cells through an Integrin α5– and Integrin β3–Dependent Mechanism

(2014) Eva Juengel et al.   NEOPLASIA

 1 Integrin Targeting Potentiates Antiangiogenic Therapy and Inhibits the Growth of Bevacizumab-Resistant Glioblastoma

(2013) W. S. Carbonell et al.   CANCER RESEARCH

Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer

(2013) Gopa Iyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells

(2012) I Tsaur et al.   BRITISH JOURNAL OF CANCER

The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line

(2011) Igor Tsaur et al.   CANCER LETTERS

Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells

(2011) Steffen Wedel et al.   CLINICAL & EXPERIMENTAL METASTASIS

Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder

(2011) Chih-Hao Sun et al.   HISTOPATHOLOGY

Functional elucidation and methylation-mediated downregulation of ITGA5 gene in breast cancer cell line MDA-MB-468

(2010) Zhengyu Fang et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract

(2009) Joaquim Bellmunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhancing Mammalian Target of Rapamycin (mTOR)-Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation

(2008) X. Wang et al.   CANCER RESEARCH